{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ALVAC-HIV+%28vCP1452%29", "query": { "intervention": "ALVAC-HIV (vCP1452)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ALVAC-HIV+%28vCP1452%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T05:23:28.347Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00027261", "title": "Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "HIV Seronegativity" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 110, "start_date": null, "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 13, "location_summary": "Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027261" }, { "nct_id": "NCT00000879", "title": "A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "HIV Seronegativity" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "MN rgp120/HIV-1 and GNE8 rgp120/HIV-1", "type": "BIOLOGICAL" }, { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "3 Days", "sex": "ALL", "summary": "0 Days to 3 Days" }, "enrollment_count": 48, "start_date": null, "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 17, "location_summary": "Long Beach, California • Orange, California • San Francisco, California + 11 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000879" }, { "nct_id": "NCT00026624", "title": "Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "Keyhole-Limpet Hemocyanin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026624" }, { "nct_id": "NCT00000904", "title": "Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "gp160 MN/LAI-2", "type": "BIOLOGICAL" }, { "name": "ALVAC(1)120(B,MN)GNP (vCP1433)", "type": "BIOLOGICAL" }, { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" }, { "name": "ALVAC-RG Rabies Glycoprotein (vCP65)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 100, "start_date": null, "completion_date": "1999-08", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000904" }, { "nct_id": "NCT00006495", "title": "Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "HIV-1 Immunogen", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": null, "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 9, "location_summary": "Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006495" }, { "nct_id": "NCT00219362", "title": "Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "one injection of vCP1452 at W0, W4, W8 and W20", "type": "BIOLOGICAL" }, { "name": "one injection of vCP1452 at W4, W8 and W20", "type": "BIOLOGICAL" }, { "name": "one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Objectif Recherche Vaccins SIDA", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2004-04", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2009-11-25", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00219362" }, { "nct_id": "NCT00056797", "title": "Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC HIV vaccine (vCP1452)", "type": "BIOLOGICAL" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 92, "start_date": "2002-03", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2016-12-14", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056797" }, { "nct_id": "NCT00076063", "title": "A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC-HIV (vCP1452)", "type": "BIOLOGICAL" }, { "name": "LIPO-5", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 174, "start_date": "2004-03", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076063" }, { "nct_id": "NCT00005758", "title": "Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "HIV-1 Immunogen", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 472, "start_date": null, "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 17, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005758" }, { "nct_id": "NCT00006291", "title": "Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": null, "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-28T05:23:28.347Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006291" } ] }